Jeffrey Dierks Sells 1,629 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Stock

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) insider Jeffrey Dierks sold 1,629 shares of the business’s stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $38.02, for a total value of $61,934.58. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Jeffrey Dierks also recently made the following trade(s):

• On Friday, January 24th, Jeffrey Dierks sold 13,125 shares of Harmony Biosciences stock. The shares were sold at an average price of $37.31, for a total transaction of $489,693.75.
• On Tuesday, January 21st, Jeffrey Dierks sold 1,123 shares of Harmony Biosciences stock. The shares were sold at an average price of $40.00, for a total value of $44,920.00.
• On Wednesday, January 15th, Jeffrey Dierks sold 10,507 shares of Harmony Biosciences stock. The shares were sold at an average price of $37.01, for a total value of $388,864.07.

Harmony Biosciences Stock Performance

HRMY opened at $38.82 on Thursday. Harmony Biosciences Holdings, Inc. has a twelve month low of $28.14 and a twelve month high of $41.61. The stock has a market cap of $2.21 billion, a PE ratio of 18.40, a price-to-earnings-growth ratio of 0.51 and a beta of 0.78. The business’s 50 day moving average is $35.20 and its 200-day moving average is $35.22. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28.

Harmony Biosciences (NASDAQ:HRMY) last announced its earnings results on Tuesday, October 29th. The company reported $0.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.15. The firm had revenue of $186.00 million during the quarter, compared to analyst estimates of $184.07 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. Harmony Biosciences’s revenue was up 16.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.63 EPS. On average, analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Institutional Investors Weigh In On Harmony Biosciences

A number of large investors have recently added to or reduced their stakes in HRMY. GAMMA Investing LLC lifted its position in Harmony Biosciences by 92.6% during the 4th quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock worth $31,000 after acquiring an additional 436 shares during the last quarter. Mendota Financial Group LLC lifted its position in shares of Harmony Biosciences by 24,125.0% during the 4th quarter. Mendota Financial Group LLC now owns 969 shares of the company’s stock worth $33,000 after purchasing an additional 965 shares during the last quarter. CWM LLC boosted its stake in Harmony Biosciences by 111.7% during the 3rd quarter. CWM LLC now owns 1,469 shares of the company’s stock valued at $59,000 after purchasing an additional 775 shares during the period. Quarry LP acquired a new stake in Harmony Biosciences in the 2nd quarter valued at approximately $62,000. Finally, KBC Group NV increased its position in Harmony Biosciences by 79.9% in the 4th quarter. KBC Group NV now owns 1,844 shares of the company’s stock worth $63,000 after buying an additional 819 shares during the period. Institutional investors own 86.23% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on HRMY shares. HC Wainwright reaffirmed a “buy” rating and set a $75.00 price target on shares of Harmony Biosciences in a research report on Monday. Cantor Fitzgerald lifted their target price on Harmony Biosciences from $51.00 to $58.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 30th. Needham & Company LLC reissued a “buy” rating and set a $52.00 price target on shares of Harmony Biosciences in a research report on Monday, January 13th. Raymond James reaffirmed an “outperform” rating and issued a $40.00 price objective on shares of Harmony Biosciences in a report on Thursday, October 10th. Finally, Mizuho increased their target price on shares of Harmony Biosciences from $42.00 to $52.00 and gave the stock an “outperform” rating in a report on Thursday, October 10th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, Harmony Biosciences has a consensus rating of “Buy” and an average price target of $55.00.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.